Investors / United States / MPM BioImpact
MPM BioImpact
Venture capital · Boston, MA, United States · North America
MPM BioImpact is a biotechnology investment firm that builds and invests in private and public companies across the drug development process. It manages over $3 billion across early-stage venture funds, private/public impact funds and a public equities fund.
Invests inHealthcare & Biotech
In its own wordsbiotechoncologycell therapygene therapyrna therapyimpact investing
Your fit with MPM BioImpact
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsMPM BioImpact lists 19 checked portfolio companies on its own site and is named in 3 funding rounds, 1 of them as lead. Its most frequent entry is Series B, 67% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 82% of its companies are based in United States. It invests most often alongside Vida Ventures, RA Capital and Agent Capital.
Counts come from funding rounds that name MPM BioImpact, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not MPM BioImpact's whole history. Rounds on record name 3 companies; its own site lists 19. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 33% |
| Series A | 0% |
| Series B | 67% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 2 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 49th | 19 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 64th | 33% of entries at pre-seed or seed |
| Evidence | 78th | 11% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 59th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Vida Ventures | 4 |
| RA Capital | 3 |
| Agent Capital | 2 |
| DCVC | 2 |
| Droia Ventures | 2 |
| Novartis Venture Fund | 2 |
| Sanofi Ventures | 2 |
| SoftBank Vision Fund | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers1895%
- No longer answers00%
- Points to another company15%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare MPM BioImpact head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with MPM BioImpact| Date | Company | Stage |
|---|---|---|
| 11 Aug 2026 | Seed Led | |
| 18 Mar 2026 | Series B | |
| 1 Dec 2025 | Series B |
Round details for MPM BioImpact
Amounts, full round histories and every co-investor in MPM BioImpact's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
19 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Aktis Oncology develops targeted alpha-based radiopharmaceuticals for the treatment of cancer patients. | Healthcare & Biotech | Portfolio page | ||
| Arialys Therapeutics is developing new precision medicines to specifically block the effect of pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease. | Healthcare & Biotech | Portfolio page | ||
| AshiBio is developing novel therapies for patients with bone and connective tissue disorders | Healthcare & Biotech | Portfolio page | ||
| AstronauTx develops therapeutics to treat neurological disorders by improving sleep architecture | Healthcare & Biotech | Portfolio page | ||
| Crossbow Therapeutics develops antibody therapeutics to treat cancer. | Healthcare & Biotech | Mar 2026Series B | Page + round | |
| Portfolio page | ||||
| Dyne Therapeutics develops nucleic acid therapies for rare diseases. | Healthcare & Biotech | Portfolio page | ||
| ElevateBio partners with innovators to identify drug targets and manufacture clinical and commercial products to address unmet medical needs through cell and gene therapies | Healthcare & Biotech | Portfolio page | ||
| Entrada Therapeutics is working to treat devastating diseases with intracellular therapeutics | Healthcare & Biotech | Portfolio page | ||
| Fable Therapeutics operates at the intersection of sophisticated protein engineering and metabolic disease. | Healthcare & Biotech | Portfolio page | ||
| Frontier Medicines is unlocking the proteome to develop a differentiated pipeline of small-molecule drugs against previously undruggable targets | Healthcare & Biotech | Portfolio page | ||
| K2 Therapeutics is a biotech company that identifies and develops innovative assets into medicines through a disciplined development approach | Healthcare & Biotech | Aug 2026Seed | Page + round | |
| NextPoint Therapeutics is developing precision therapeutics through scientific work on the novel B7-H7/HHLA2 axis for cancer treatment. | Healthcare & Biotech | Portfolio page | ||
| Photys Therapeutics is a proximity-based therapeutics company advancing a new generation of targeted protein modulation medicines. | Healthcare & Biotech | Portfolio page | ||
| Protego Bio is a clinical-stage biotechnology company developing small molecule therapies for protein misfolding diseases, including AL amyloidosis. | Healthcare & Biotech | Dec 2025Series B | Funding round | |
| ReCode Therapeutics develops therapeutics for genetically defined diseases with a focus on cystic fibrosis. | Healthcare & Biotech | Portfolio page | ||
| Reunion Neuroscience is a clinical-stage biopharmaceutical company developing innovative therapeutics for underserved mental health disorders | Healthcare & Biotech | Portfolio page | ||
| Tizona Therapeutics is developing first-in-class immunotherapies for cancer treatment | Healthcare & Biotech | Portfolio page | ||
| Umoja Biopharma develops in vivo CAR T cell therapies for the treatment of cancers and other conditions. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- mpmbioimpact.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 1 Dec 2025
- Companies checked
- 19
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get MPM BioImpact's profile as data
Pull MPM BioImpact's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/mpmbioimpact.com
# also
GET /v1/firms/mpmbioimpact.com/portfolio
GET /v1/firms/mpmbioimpact.com/coinvestors
GET /v1/firms/mpmbioimpact.com/news